Anafranil
- Generic Name: clomipramine hcl
- Brand Name: Anafranil
Anafranil (Clomipramine Hcl) side effects drug center
- Related Drugs
- Drug Comparison
- Anafranil User Reviews
Anafranil Side Effects Center
What Is Anafranil?
Anafranil (clomipramine hydrochloride) is a tricyclic antidepressant used to treat symptoms of obsessive-compulsive disorder (OCD) such as recurrent thoughts or feelings and repetitive actions. Anafranil is available in generic form.
What Are Side Effects of Anafranil?
Common side effects of Anafranil include:
- dizziness,
- drowsiness,
- dry mouth,
- constipation,
- stomach upset,
- nausea,
- vomiting,
- changes in appetite or weight,
- flushing,
- increased sweating,
- tiredness,
- blurred vision or vision changes,
- anxiety,
- restlessness,
- sleep problems (insomnia),
- memory problems,
- trouble concentrating,
- numbness or tingling,
- decreased sex drive,
- impotence, or
- difficulty having an orgasm.
Tell your doctor if you have unlikely but serious side effects of Anafranil including:
- mental/mood changes (e.g., confusion, depression),
- enlarged or painful breasts,
- unwanted breast milk production,
- irregular or painful menstrual periods,
- muscle stiffness,
- ringing in the ears,
- shakiness (tremors), or
- trouble urinating.
Dosage for Anafranil
The adult starting dose of Anafranil is 25 mg daily and gradually increased, as tolerated, to approximately 100 mg during the first 2 weeks. Maximum dose is 250 mg daily. Consult your doctor for pediatric or adolescent dosing.
What Drugs, Substances, or Supplements Interact with Anafranil?
Anafranil may interact with SSRI antidepressants, cimetidine, guanethidine, methylphenidate, phenytoin, warfarin, heart or blood pressure medications, heart rhythm medications, or anti-psychotic medications. Many other drugs can interact with Anafranil. Tell your doctor all medications you use. Anafranil should be used only when prescribed during pregnancy. Newborns exposed to this drug during pregnancy may experience withdrawal symptoms or side effects.
Anafranil During Pregnancy and Breastfeeding
Tell your doctor if you notice jitteriness, shaking, feeding problems, fast breathing, or seizures in your newborn. This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.
Additional Information
Our Anafranil (clomipramine hydrochloride) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Anafranil Consumer Information
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Seek medical treatment if you have a serious drug reaction that can affect many parts of your body. Symptoms may include: skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.
Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Call your doctor at once if you have:
- low sodium level --headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady;
- blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
- confusion, extreme fear, thoughts of hurting yourself;
- pain or burning when you urinate; or
- a seizure (convulsions).
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
Common side effects may include:
- feeling dizzy, drowsy, tired, or nervous;
- tremors, jerking muscle movements;
- sweating;
- changes in appetite or weight;
- urination problems;
- vision changes; or
- decreased sex drive, impotence, or difficulty having an orgasm.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Anafranil (Clomipramine Hcl)
Anafranil Professional Information
SIDE EFFECTS
Commonly Observed
The most commonly observed adverse events associated with the use of Anafranil and not seen at an equivalent incidence among placebo-treated patients were gastrointestinal complaints, including dry mouth, constipation, nausea, dyspepsia, and anorexia; nervous system complaints, including somnolence, tremor, dizziness, nervousness, and myoclonus; genitourinary complaints, including changed libido, ejaculatory failure, impotence, and micturition disorder; and other miscellaneous complaints, including fatigue, sweating, increased appetite, weight gain, and visual changes.
Leading To Discontinuation Of Treatment
Approximately 20% of 3616 patients who received Anafranil in U.S. premarketing clinical trials discontinued treatment because of an adverse event. Approximately one-half of the patients who discontinued (9% of the total) had multiple complaints, none of which could be classified as primary. Where a primary reason for discontinuation could be identified, most patients discontinued because of nervous system complaints (5.4%), primarily somnolence. The second-most-frequent reason for discontinuation was digestive system complaints (1.3%), primarily vomiting and nausea.
There was no apparent relationship between the adverse events and elevated plasma drug concentrations.
Incidence In Controlled Clinical Trials
The following table enumerates adverse events that occurred at an incidence of 1% or greater among patients with OCD who received Anafranil in adult or pediatric placebo-controlled clinical trials. The frequencies were obtained from pooled data of clinical trials involving either adults receiving Anafranil (N=322) or placebo (N=319) or children treated with Anafranil (N=46) or placebo (N=44). The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the populations studied.
Incidence of Treatment-Emergent Adverse Experience in
Placebo- Controlled Clinical Trials (Percentage of Patients Reporting Event)
Body System/ Adverse Event* | Adults | Children and Adolescents | ||
Anafranil (N=322) |
Placebo (N=319) |
Anafranil (N=46) |
Placebo (N=44) |
|
Nervous System | ||||
Somnolence | 54 | 16 | 46 | 11 |
Tremor | 54 | 2 | 33 | 2 |
Dizziness | 54 | 14 | 41 | 14 |
Headache | 52 | 41 | 28 | 34 |
Insomnia | 25 | 15 | 11 | 7 |
Libido change | 21 | 3 | - | - |
Nervousness | 18 | 2 | 4 | 2 |
Myoclonus | 13 | - | 2 | - |
Increased appetite | 11 | 2 | - | 2 |
Paresthesia | 9 | 3 | 2 | 2 |
Memory impairment | 9 | 1 | 7 | 2 |
Anxiety | 9 | 4 | 2 | - |
Twitching | 7 | 1 | 4 | 5 |
Impaired concentration | 5 | 2 | - | - |
Depression | 5 | 1 | - | - |
Hypertonia | 4 | 1 | 2 | - |
Sleep disorder | 4 | - | 9 | 5 |
Psychosomatic disorder | 3 | - | - | - |
Yawning | 3 | - | - | - |
Confusion | 3 | - | 2 | - |
Speech disorder | 3 | - | - | - |
Abnormal dreaming | 3 | - | - | 2 |
Agitation | 3 | - | - | - |
Migraine | 3 | - | - | - |
Depersonalization | 2 | - | 2 | - |
Irritability | 2 | 2 | 2 | - |
Emotional lability | 2 | - | - | 2 |
Panic reaction | 1 | - | 2 | - |
Aggressive reaction | - | - | 2 | - |
Paresis | 2 | |||
Skin and Appendages | ||||
Increased sweating | 29 | 3 | 9 | - |
Rash | 8 | 1 | 4 | 2 |
Pruritus | 6 | - | 2 | 2 |
Dermatitis | 2 | - | - | 2 |
Acne | 2 | 2 | - | 5 |
Dry skin | 2 | - | - | 5 |
Urticaria | 1 | - | - | - |
Abnormal skin odor | - | - | 2 | - |
Digestive System | ||||
Dry mouth | 84 | 17 | 63 | 16 |
Constipation | 47 | 11 | 22 | 9 |
Nausea | 33 | 14 | 9 | 11 |
Dyspepsia | 22 | 10 | 13 | 2 |
Diarrhea | 13 | 9 | 7 | 5 |
Anorexia | 12 | - | 22 | 2 |
Abdominal pain | 11 | 9 | 13 | 16 |
Vomiting | 7 | 2 | 7 | - |
Flatulence | 6 | 3 | - | 2 |
Tooth disorder | 5 | - | - | - |
Gastrointestinal disorder | 2 | - | - | 2 |
Dysphagia | 2 | - | - | - |
Esophagitis | 1 | - | - | - |
Eructation | - | - | 2 | 2 |
Ulcerative stomatitis | - | - | 2 | - |
Body as a Whole | ||||
Fatigue | 39 | 18 | 35 | 9 |
Weight increase | 18 | 1 | 2 | - |
Flushing | 8 | - | 7 | - |
Hot flushes | 5 | - | 2 | - |
Chest pain | 4 | 4 | 7 | - |
Fever | 4 | - | 2 | 7 |
Allergy | 3 | 3 | 7 | 5 |
Pain | 3 | 2 | 4 | 2 |
Local edema | 2 | 4 | - | - |
Chills | 2 | 1 | - | - |
Weight decrease | - | - | 7 | - |
Otitis media | - | - | 4 | 5 |
Asthenia | - | - | 2 | - |
Halitosis | - | - | 2 | - |
Cardiovascular System | ||||
Postural hypotension | 6 | - | 4 | - |
Palpitation | 4 | 2 | 4 | - |
Tachycardia | 4 | - | 2 | - |
Syncope | - | - | 2 | - |
Respiratory System | ||||
Pharyngitis | 14 | 9 | - | 5 |
Rhinitis | 12 | 10 | 7 | 9 |
Sinusitis | 6 | 4 | 2 | 5 |
Coughing | 6 | 6 | 4 | 5 |
Bronchospasm | 2 | - | 7 | 2 |
Epistaxis | 2 | - | - | 2 |
Dyspnea | - | - | 2 | - |
Laryngitis | - | 1 | 2 | - |
Urogenital System Male and Female Patients Combined | ||||
Micturition disorder | 14 | 2 | 4 | 2 |
Urinary tract infection | 6 | 1 | - | - |
Micturition frequency | 5 | 3 | - | - |
Urinary retention | 2 | - | 7 | - |
Dysuria | 2 | 2 | - | - |
Cystitis | 2 | - | - | - |
Female Patients Only | (N=182) | (N=167) | (N=10) | (N=21) |
Dysmenorrhea | 12 | 14 | 10 | 10 |
Lactation (nonpuerperal) | 4 | - | - | - |
Menstrual disorder | 4 | 2 | - | - |
Vaginitis | 2 | - | - | - |
Leukorrhea | 2 | - | - | - |
Breast enlargement | 2 | - | - | - |
Breast pain | 1 | - | - | - |
Amenorrhea | 1 | - | - | - |
Male Patients Only | (N=140) | (N=152) | (N=36) | (N=23) |
Ejaculation failure | 42 | 2 | 6 | - |
Impotence | 20 | 3 | - | - |
Special Senses | ||||
Abnormal vision | 18 | 4 | 7 | 2 |
Taste perversion | 8 | - | 4 | - |
Tinnitus | 6 | - | 4 | - |
Abnormal lacrimation | 3 | 2 | - | - |
Mydriasis | 2 | - | - | - |
Conjunctivitis | 1 | - | - | - |
Anisocoria | - | - | 2 | - |
Blepharospasm | - | - | 2 | - |
Ocular allergy | - | - | 2 | - |
Vestibular disorder | - | - | 2 | 2 |
Musculoskeletal | ||||
Myalgia | 13 | 9 | - | - |
Back pain | 6 | 6 | - | - |
Arthralgia | 3 | 5 | - | - |
Muscle weakness | 1 | - | 2 | - |
Hemic and Lymphatic | ||||
Purpura | 3 | - | - | - |
Anemia | - | - | 2 | 2 |
Metabolic and Nutritional | ||||
Thirst | 2 | 2 | - | 2 |
*Events reported by at least 1% of Anafranil patients are included. |
Other Events Observed During The Premarketing Evaluation Of Anafranil
During clinical testing in the U.S., multiple doses of Anafranil were administered to approximately 3600 subjects. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.
In the tabulations that follow, a modified World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the 3525 individuals exposed to Anafranil who experienced an event of the type cited on at least one occasion while receiving Anafranil. All events are included except those already listed in the previous table, those reported in terms so general as to be uninformative, and those in which an association with the drug was remote. It is important to emphasize that although the events reported occurred during treatment with Anafranil, they were not necessarily caused by it.
Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in less than 1/1000 patients.
Body as a Whole - Infrequent - general edema, increased susceptibility to infection, malaise. Rare - dependent edema, withdrawal syndrome.
Cardiovascular System - Infrequent - abnormal ECG, arrhythmia, bradycardia, cardiac arrest, extrasystoles, pallor. Rare - aneurysm, atrial flutter, bundle branch block, cardiac failure, cerebral hemorrhage, heart block, myocardial infarction, myocardial ischemia, peripheral ischemia, thrombophlebitis, vasospasm, ventricular tachycardia.
Digestive System - Infrequent - abnormal hepatic function, blood in stool, colitis, duodenitis, gastric ulcer, gastritis, gastroesophageal reflux, gingivitis, glossitis, hemorrhoids, hepatitis, increased saliva, irritable bowel syndrome, peptic ulcer, rectal hemorrhage, tongue ulceration, tooth caries. Rare - cheilitis, chronic enteritis, discolored feces, gastric dilatation, gingival bleeding, hiccup, intestinal obstruction, oral/pharyngeal edema, paralytic ileus, salivary gland enlargement.
Endocrine System - Infrequent - hypothyroidism. Rare - goiter, gynecomastia, hyperthyroidism.
Hemic and Lymphatic System - Infrequent - lymphadenopathy. Rare - leukemoid reaction, lymphoma-like disorder, marrow depression.
Metabolic and Nutritional Disorder - Infrequent - dehydration, diabetes mellitus, gout, hypercholesterolemia, hyperglycemia, hyperuricemia, hypokalemia. Rare - fat intolerance, glycosuria.
Musculoskeletal System - Infrequent - arthrosis. Rare - dystonia, exostosis, lupus erythematosus rash, bruising, myopathy, myositis, polyarteritis nodosa, torticollis.
Nervous System - Frequent - abnormal thinking, vertigo. Infrequent - abnormal coordination, abnormal EEG, abnormal gait, apathy, ataxia, coma, convulsions, delirium, delusion, dyskinesia, dysphonia, encephalopathy, euphoria, extrapyramidal disorder, hallucinations, hostility, hyperkinesia, hypnagogic hallucinations, hypokinesia, leg cramps, manic reaction, neuralgia, paranoia, phobic disorder, psychosis, sensory disturbance, somnambulism, stimulation, suicidal ideation, suicide attempt, teeth-grinding. Rare - anticholinergic syndrome, aphasia, apraxia, catalepsy, cholinergic syndrome, choreoathetosis, generalized spasm, hemiparesis, hyperesthesia, hyperreflexia, hypoesthesia, illusion, impaired impulse control, indecisiveness, mutism, neuropathy, nystagmus, oculogyric crisis, oculomotor nerve paralysis, schizophrenic reaction, stupor, suicide.
Respiratory System - Infrequent - bronchitis, hyperventilation, increased sputum, pneumonia. Rare - cyanosis, hemoptysis, hypoventilation, laryngismus.
Skin and Appendages - Infrequent - alopecia, cellulitis, cyst, eczema, erythematous rash, genital pruritus, maculopapular rash, photosensitivity reaction, psoriasis, pustular rash, skin discoloration. Rare - chloasma, folliculitis, hypertrichosis, piloerection, seborrhea, skin hypertrophy, skin ulceration.
Special Senses - Infrequent - abnormal accommodation, deafness, diplopia, earache, eye pain, foreign body sensation, hyperacusis, parosmia, photophobia, scleritis, taste loss. Rare - blepharitis, chromatopsia, conjunctival hemorrhage, exophthalmos, glaucoma, keratitis, labyrinth disorder, night blindness, retinal disorder, strabismus, visual field defect.
Urogenital System - Infrequent - endometriosis, epididymitis, hematuria, nocturia, oliguria, ovarian cyst, perineal pain, polyuria, prostatic disorder, renal calculus, renal pain, urethral disorder, urinary incontinence, uterine hemorrhage, vaginal hemorrhage. Rare - albuminuria, anorgasmy, breast engorgement, breast fibroadenosis, cervical dysplasia, endometrial hyperplasia, premature ejaculation, pyelonephritis, pyuria, renal cyst, uterine inflammation, vulvar disorder.
Postmarketing Experience
The following adverse drug reaction has been reported during post-approval use of Anafranil. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency.
Eye Disorders - Angle-closure glaucoma.
Immune System Disorders - Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).
Metabolism and Nutrition Disorders - Hyponatremia.
Endocrine Disorders - Syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Read the entire FDA prescribing information for Anafranil (Clomipramine Hcl)
© Anafranil Patient Information is supplied by Cerner Multum, Inc. and Anafranil Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.